<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899024</url>
  </required_header>
  <id_info>
    <org_study_id>20200231</org_study_id>
    <secondary_id>R01DA051848</secondary_id>
    <nct_id>NCT04899024</nct_id>
  </id_info>
  <brief_title>PrEP Affect Regulation Treatment Innovation</brief_title>
  <acronym>PARTI</acronym>
  <official_title>Optimizing PrEP Adherence in Sexual Minority Men Who Use Stimulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-site randomized controlled trial enrolling sexual minority men who use stimulants&#xD;
      and are currently taking pre-exposure prophylaxis (PrEP). This randomized controlled trial&#xD;
      will test the efficacy of a PrEP Affect Regulation Treatment Innovation (PARTI) condition&#xD;
      comprised of a 5-session positive affect intervention delivered during smartphone-based&#xD;
      Contingency Management (CM) for directly observed PrEP doses (PARTI+CM) compared to an&#xD;
      attention-control condition delivered during CM. The primary outcome is HIV acquisition risk&#xD;
      measured using a combination of tenofovir-diphosphate levels in dried blood spots that are&#xD;
      indicative of sub-optimal adherence to PrEP and recent condomless anal sex.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Engaging HIV Acquisition Risk</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants engaging in HIV acquisition risk (i.e., defined as tenofovir - diphosphate levels &lt; 700 fmol per punch from dried blood spots and any self-reported recent condomless anal sex)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PrEP Persistence</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants who continue taking PrEP medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in PrEP Care</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants who report attending a medical visit with the PrEP provider in the past three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Stimulant Use Severity</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) provides validated composite scores indexing the severity of cocaine and amphetamine use (Mild = 0-3; Moderate = 4-26; Severe = 27 or greater).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Affect</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Mean positive affect score as measured by the modified Differential Emotions Scale (Range 0-104) with higher scores being indicative of higher positive affect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Medication Adherence</condition>
  <condition>HIV Prevention</condition>
  <condition>Stimulant Use</condition>
  <arm_group>
    <arm_group_label>PARTI and CM (Contingency Management)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention-Control and CM (Contingency Management)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PARTI</intervention_name>
    <description>PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.</description>
    <arm_group_label>PARTI and CM (Contingency Management)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attention-Control</intervention_name>
    <description>Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.</description>
    <arm_group_label>Attention-Control and CM (Contingency Management)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management for PrEP Adherence</intervention_name>
    <description>Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.</description>
    <arm_group_label>Attention-Control and CM (Contingency Management)</arm_group_label>
    <arm_group_label>PARTI and CM (Contingency Management)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Assigned male at birth&#xD;
&#xD;
          -  Identifies as male&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Reads and speaks English&#xD;
&#xD;
          -  Past 6 months, reports condomless anal sex (CAS) with men&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Currently has an active prescription for daily oral PrEP and reports any non-adherence&#xD;
             in the past month&#xD;
&#xD;
          -  Has an iPhone or Android smartphone&#xD;
&#xD;
          -  Screens positive for a moderate or severe stimulant use disorder with an abbreviated&#xD;
             version of the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)&#xD;
&#xD;
          -  Lives within catchment area (South Florida, San Francisco Bay area)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Unwilling to participate in smartphone-based CM for directly observed PrEP doses&#xD;
&#xD;
          -  Unwilling to provide dried blood spot (DBS) specimen&#xD;
&#xD;
          -  Plans to move out of the state in the next 6 months&#xD;
&#xD;
          -  Not taking PrEP daily (e.g., if taking intermittent 2-1-1 dosing)&#xD;
&#xD;
          -  Switched from Truvada to Descovy in the last 5 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam W Carrico, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam W. Carrico, PhD</last_name>
    <phone>305-243-6947</phone>
    <email>a.carrico@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lara Coffin, MPH</last_name>
      <phone>415-502-5216</phone>
      <email>Lara.Coffin@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chelsea Henderson</last_name>
      <phone>954-802-9318</phone>
      <email>cxv446@miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Omar Valentin</last_name>
      <phone>787-565-1444</phone>
      <email>orv5@med.miami.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Carrico</investigator_full_name>
    <investigator_title>Professor, Director</investigator_title>
  </responsible_party>
  <keyword>Sexual Minority Men</keyword>
  <keyword>HIV</keyword>
  <keyword>PrEP Adherence</keyword>
  <keyword>Contingency Management</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

